Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 249Other hematologic neoplasm 135Plasma cell 10Myeloid 6Genitourinary 4Gastrointestinal 4CNS 4Thoracic 3Classical hematology 3Tumor-Agnostic 2Dermatologic 2Breast 2NET 1Head & Neck 1Endocrine 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

Cisplatin 619pembrolizumab 323Radiotherapy 319Cetuximab 274Docetaxel 220Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 74Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 48Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 43tislelizumab 42Standard of Care 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × ibrutinib × Head & Neck × Clear all
NCT03646461 2026-05-22

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

University of California, San Diego

Phase 2 Terminated
5 enrolled 9 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡